Core Insights - The Hong Kong Innovative Drug 50 ETF (513780) experienced a 2.67% increase on September 30, with a trading volume of 682 million yuan [1] - The fund's shares decreased by 20 million, bringing the total shares to 1.854 billion, while the shares increased by 483 million over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 3.651 billion yuan [1] - The fund's performance benchmark is the CSI Hong Kong Stock Connect Innovative Drug Index return rate, adjusted for valuation exchange rates [1] - The fund is managed by Invesco Great Wall Fund Management Co., with fund managers Jin Huang and Zhang Xiaonan [1] - Since its establishment on October 16, 2024, the fund has achieved a return of 96.97%, with a monthly return of 4.75% [1]
9月30日港股创新药50ETF（513780）份额减少2000.00万份
Xin Lang Cai Jing·2025-10-09 01:12